AHCPR Becomes AHRQ, But Call It ARC

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

VT3989 Receives Orphan Drug Designation for the Treatment of Mesothelioma

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

An ongoing, open-label phase 1 study evaluating VT3989 in mesothelioma revealed positive early efficacy and encouraging safety with the agent.

Roman Fabbricatore

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

An ongoing, open-label phase 1 study evaluating VT3989 in mesothelioma revealed positive early efficacy and encouraging safety with the agent.

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD

IMM2510/AXN-2510 Combo Yields Preliminary Responses in Advanced NSCLC

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

The treatment combination elicited partial responses in 80% of patients with squamous NSCLC and 46% in nonsquamous NSCLC.

Discussing Early ctDNA Detection Through MCED Blood Tests

The treatment combination elicited partial responses in 80% of patients with squamous NSCLC and 46% in nonsquamous NSCLC.

A recently published study showed that a multicancer early detection blood test was able to identify cancer 3 or more years before a diagnosis.

CAR T-Cell Therapies Show Superior Efficacy, Safety in Multiple Myeloma

A recently published study showed that a multicancer early detection blood test was able to identify cancer 3 or more years before a diagnosis.

Related Content

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

VT3989 Receives Orphan Drug Designation for the Treatment of Mesothelioma

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

Roman Fabbricatore

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

An ongoing, open-label phase 1 study evaluating VT3989 in mesothelioma revealed positive early efficacy and encouraging safety with the agent.

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD

IMM2510/AXN-2510 Combo Yields Preliminary Responses in Advanced NSCLC

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Discussing Early ctDNA Detection Through MCED Blood Tests

The treatment combination elicited partial responses in 80% of patients with squamous NSCLC and 46% in nonsquamous NSCLC.